ストックスクリーナーアプリを入手
5.08
3.79%
-0.20
アフターアワーズ：
5.18
0.10
+1.97%
前日終値:
$5.28
開ける：
$5.27
24時間の取引高:
71,789
Relative Volume:
0.04
時価総額：
$23.25M
収益：
-
当期純損益:
$-54.66M
株価収益率:
-0.2663
EPS:
-19.0729
ネットキャッシュフロー:
$-49.98M
1週間 パフォーマンス:
-16.99%
1か月 パフォーマンス:
-14.04%
6か月 パフォーマンス:
-50.15%
1年 パフォーマンス:
-12.11%
1日の値動き範囲:
$5.0234
$5.56
1週間の範囲:
$4.64
$6.30
52週間の値動き範囲:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
名前
Nextcure Inc
セクター
電話
240-399-4900
住所
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.08 | 23.25M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-07 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-03-05 | アップグレード | Truist | Hold → Buy |
| 2021-01-15 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-07-16 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-07-13 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-13 | ダウングレード | SunTrust | Buy → Hold |
| 2020-06-01 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-03-24 | 開始されました | The Benchmark Company | Buy |
| 2020-03-02 | 開始されました | ROTH Capital | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-05 | 開始されました | Needham | Buy |
| 2019-11-26 | 開始されました | BTIG Research | Buy |
| 2019-07-09 | 開始されました | BofA/Merrill | Buy |
| 2019-06-03 | 開始されました | Morgan Stanley | Overweight |
| 2019-06-03 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Nextcure Inc (NXTC) 最新ニュース
NextCure Faces Court Review of Reverse Stock Split - TipRanks
About 90% of votes cast backed a share split. NextCure (NXTC) now asks a court to validate it. - Stock Titan
NextCure seeks Delaware court validation of 2025 1-for-12 reverse split ahead of Avere merger - TradingView
Nextcure Stock Price Forecast. Should You Buy NXTC? - StockInvest.us
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - seekingalpha.com
NextCure Inc (NASDAQ: NXTC) Stock Price, News & Analysis - Kalkine
NXTC|NextCure Inc|Price:7.860|Chg%:+0.040 - TradingKey
NextCure Ends Beltsville Lease to Cut Operating Costs - TipRanks
About 30,000 sq ft of lab as NextCure (NXTC) exits Maryland site—what it paid to leave early - Stock Titan
NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road - marketscreener.com
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds NextCure, Inc. Investors of Important November 20 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact FirmNXTC - TMX Newsfile
NextCure - thepharmaletter.com
NextCure (NXTC) Q2 2026 Earnings: Profit Per Share Falls Below Its Benchmark for the Current Session - vinanet.vn
NextCure (NASDAQ: NXTC) plans Avere merger backed by $820M raise - Stock Titan
NextCure (NXTC) Share-Price Review: Declines 11.15% to $6.85 at the Close; Current Range Read: the Near-Term Reference Band Stretches From $6.51 to $7.19 under the Current SnapshotExtension Target - vinanet.vn
Ikarian Capital discloses 9.99% NextCure (NXTC) stake including large warrant position - Stock Titan
NextCure (NXTC) gains 15.8% beneficial owner in ADAR1 Capital and manager - Stock Titan
NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake - Stock Titan
Affinity Asset Advisors discloses 6.4% NextCure (NXTC) stake via stock and warrants - Stock Titan
NextCure stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Major Former Stakeholder Makes a Significant Move in NextCure Stock - TipRanks
Simcere Zaiming sells $184,800 of NextCure stock By Investing.com - Investing.com India
Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership - Stock Titan
Simcere Zaiming sells $184,800 of NextCure stock - Investing.com
Simcere group (NXTC) trims NextCure stake, ends 10% beneficial ownership - Stock Titan
RTW Biotech's Avere to go public in US in reverse merger with NextCure - London South East
NXTC Q2 2026 Earnings: 42% EPS Miss Yet Shares Rally 21.4%Earnings Turnaround - dars.gov.et
RTW Biotech Opportunities (RTWG) Supports Avere Therapeutics’ $820M Capital Raise and NextCure Reverse Merger - Kalkine Media
NextCure (NXTC) plans reverse merger with Avere and $820M financings - Stock Titan
Xcellon Acquires 40,000 Sq ft Maryland Facility from NextCure to Deliver a cGMP-Ready CRDMO for ADCs - BioBuzz
Xcellon Biologics Acquires GMP Manufacturing Facility from NextCure, Becoming an End-to-End CRDMO for Next-Generation Bioconjugates and Complex Biologics - The Manila Times
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - Nasdaq
NextCure Inc (NXTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila Times
NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView
NextCure, Inc. Q2 2026: Net income $(14.9)M, EPS $(2.80) — 10-Q Summary - TradingView
NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan
NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock Titan
NextCure (NXTC) details two-step Avere merger plan and upcoming Form S-4 - Stock Titan
Form 4 NextCure Inc For: 4 August By Investing.com - Investing.com UK
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares - Investing.com
Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com - Investing.com India
ADAR1 Capital Management reports NextCure common share purchase worth $3.59 million - Bitget
ADAR1-managed funds buy 329,153 shares of NextCure (NXTC) - Stock Titan
Avere Therapeutics - The Pharma Letter
NextCure Inc expected to post a loss of $1.93 a shareEarnings Preview - TradingView
NextCure Stock Short Interest Rises to 32.54% | NXTC Stock News - Quiver Quantitative
NextCure, Inc. Revenue Breakdown – NASDAQ:NXTC - TradingView
NextCure (NXTC) Holds Steady Near Key Support LevelsStraddle Setup - dars.gov.et
Nextcure Inc (NXTC) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):